Literature DB >> 2677269

Is upper gastrointestinal radiography necessary in the initial management of uncomplicated dyspepsia? A randomized controlled trial comparing empiric antacid therapy plus patient reassurance with traditional care.

J D Goodson1, J W Lehmann, J M Richter, J L Read, S Atamian, G A Colditz.   

Abstract

STUDY
OBJECTIVE: To compare two strategies for the evaluation and management of patients who have had acute dyspepsia for four days or more: empiric high-dose antacid therapy combined with patient reassurance (empiric care) versus therapy based on prompt upper gastrointestinal radiography (traditional care).
DESIGN: Prospective, randomized trial. The patients in the empiric care group were reassured that upper gastrointestinal radiography was not necessary and were subsequently treated with high-dose empiric antacid therapy (15-30 ml of high-potency antacid one and three hours after meals and at bedtime). The traditional care group after meals and at bedtime). The traditional care group received upper gastrointestinal radiography as part of the initial evaluation. Subsequent treatment was determined by individual physicians based on test results. SETTINGS: Fee-for-service, hospital-based primary care practice and Veteran's Administration medical center outpatient clinic. PATIENTS: All patients were less than 70 years of age and without gastrointestinal bleeding, anemia, significant weight loss, or other specified symptoms of severe acid peptic disease. Fifty patients were randomized to traditional care, and 51 to empiric care. Pre-randomization clinical features were identical with the exception of sex distribution and baseline disability.
MEASUREMENTS AND MAIN RESULTS: After six months of follow-up, there were no significant differences in symptom scores, disability, satisfaction, and quality of life measures (as measured by the Sickness Impact Profile scores) between the two groups. Findings were unchanged when adjusted for sex, study site, alcohol consumption, and cigarette smoking. Of the radiographs obtained in the traditional care group, 13 (27%) showed duodenal ulcer disease, gastritis, or duodenitis. There were no serious complications of ulcer disease or therapy noted in either group. The average costs per patient associated with traditional care at one study site were greater, $286 versus $116 (p less than 0.0001).
CONCLUSIONS: Select patients with dyspepsia receiving a combination of reassurance and empiric antacid therapy do as well as patients whose initial management strategy includes upper gastrointestinal radiography, at a substantially lower cost.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677269     DOI: 10.1007/bf02599683

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  29 in total

1.  Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale.

Authors:  Anna Maria Carlsson
Journal:  Pain       Date:  1983-05       Impact factor: 6.961

2.  A survey of radiation doses to patients in five common diagnostic examinations.

Authors:  R M Harrison; C B Clayton; M J Day; J P Owen; M F York
Journal:  Br J Radiol       Date:  1983-06       Impact factor: 3.039

3.  A controlled randomized study of early cardiac rehabilitation: the Sickness Impact Profile as an assessment tool.

Authors:  C R Ott; E S Sivarajan; K M Newton; M J Almes; R A Bruce; M Bergner; B S Gilson
Journal:  Heart Lung       Date:  1983-03       Impact factor: 2.210

4.  Antacid pharmacology in duodenal ulcer. Effect of antacids on postcibal gastric acidity and peptic activity.

Authors:  J S Fordtran; J A Collyns
Journal:  N Engl J Med       Date:  1966-04-28       Impact factor: 91.245

5.  Measuring functional outcomes in chronic disease: a comparison of traditional scales and a self-administered health status questionnaire in patients with rheumatoid arthritis.

Authors:  R A Deyo; T S Inui; J D Leininger; S S Overman
Journal:  Med Care       Date:  1983-02       Impact factor: 2.983

6.  Diagnosis and treatment of dyspepsia. A cost-effectiveness analysis.

Authors:  L Read; T M Pass; A L Komaroff
Journal:  Med Decis Making       Date:  1982       Impact factor: 2.583

7.  Cimetidine versus intensive antacid therapy for duodenal ulcer: a multicenter trial.

Authors:  A F Ippoliti; R A Sturdevant; J I Isenberg; M Binder; R Camacho; R Cano; C Cooney; M M Kline; R L Koretz; J H Meyer; I M Samloff; A D Schwabe; E A Strom; J E Valenzuela; R H Wintroub
Journal:  Gastroenterology       Date:  1978-02       Impact factor: 22.682

8.  Non-ulcer upper dyspepsia. Aspects of pain.

Authors:  L S Jørgensen; L Bønløkke; P Wamberg
Journal:  Scand J Gastroenterol       Date:  1985-01       Impact factor: 2.423

9.  Empiric antacids and reassurance for acute dyspepsia.

Authors:  J D Goodson; J M Richter; R S Lane; T F Beckett; R G Pingree
Journal:  J Gen Intern Med       Date:  1986 Mar-Apr       Impact factor: 5.128

10.  Gastric and duodenal ulcer healing under placebo treatment.

Authors:  U Scheurer; L Witzel; F Halter; H M Keller; R Huber; R Galeazzi
Journal:  Gastroenterology       Date:  1977-05       Impact factor: 22.682

View more
  4 in total

1.  Economic costs of functional dyspepsia.

Authors:  O Nyrén; G Lindberg; E Lindström; R Seensalu
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

2.  A systematic approach to the initial evaluation of dyspepsia.

Authors:  K L Kahn
Journal:  J Gen Intern Med       Date:  1989 Sep-Oct       Impact factor: 5.128

Review 3.  Management of dyspepsia in general practice. A critical assessment.

Authors:  C Tosetti; V Stanghellini
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

4.  Are investigations anxiolytic or anxiogenic? A randomised controlled trial of neuroimaging to provide reassurance in chronic daily headache.

Authors:  L Howard; S Wessely; M Leese; L Page; P McCrone; K Husain; J Tong; A Dowson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.